Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study)

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

• Ages 18 years and older
• All sexes
• No healthy volunteers
• Adult, Older adult

Study population: Patients will be recruited by GFPC centers which is a large French network of hospitals and clinics particularly active in pneumology and thoracic oncology centers participating in clinical research. The principal investigator in each center will identify consecutive patients eligible for inclusion. Patients will be asked to confirm their consent for data collection.

Trial locations and contacts

46 sites in 1 country. Contact the study team or a site near you to ask about taking part.

About this study

Official title: Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (LUNGEVITY STUDY)

Conditions

Metastatic Lung Cancer, Metastatic NSCLC, Metastatic Small Cell Lung Cancer

Being tested

Hospital Anxiety and Depression scale (HAD), Quality of Life Questionnaire - Lung Cancer 13 (QLQ-LC13), Questionnaire Aix-Marseille-Université (AMU)

Keywords

long-terms responders, Mestastatic Lung Cancer, Metastatic NSCLC, Metastatic small cell lung cancer

Medical subject headings

Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

• Hospital Anxiety and Depression scale (HAD)Behavioural

  The HAD scale is an instrument used to screen for anxiety and depressive disorders. It comprises 14 items rated from 0 to 3. Seven questions relate to anxiety (total A) and seven others to depression (total D), giving two scores (maximum score for each = 21).

• Quality of Life Questionnaire - Lung Cancer 13 (QLQ-LC13)Behavioural

  The EORTC QLQ-LC13: a 13-item lung cancer-specific questionnaire module supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (cough, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication.

• Questionnaire Aix-Marseille-Université (AMU)Behavioural

  Data analysis will be firstly descriptive in order to report on the quality of life of respondents. Then, in a second stage, the factors associated with quality of life will be analyzed using linear or logistic regression models depending on the nature of the variable of interest.

What is being measured

The primary outcome is the main question the study is designed to answer.

1. Baseline Clinical Characteristics

   Metastatic Lung Cancer Long-Terms Responders clinical characteristics: baseline patient demographics, clinical and pathological characteristics (e.g. age, medical history, comorbidities, past history of cancer, smoking status, NSCLC or SCLC characteristics)

   Measured: At Baseline visit, on a maximum period of 12 months.

2. Aix-Marseille-University (AMU) questionnaire

   Measured: At inclusion, 6 and 12 months after inclusion and every year up to 5 years

3. EORTC QLQ-LC13

   Measured: at inclusion, 6 and 12 months after inclusion and every year up to 5 years

4. Hospital Anxiety and Depression Scale (HAD)

   Measured: at inclusion, 6 and 12 months after inclusion and every year up to 5 years

5. Treatment characteristics

   Treatment characteristics are defined by the type of treatment, the numbers of cycle and the duration of treatment.

   Measured: From date of first lung cancer treatment administration up to 5 years

6. Health status

   Health status will be evaluated using Eastern Cooperative Oncology Group performance status (PS), and collecting data new diseases, cardiovascular, diabetes, second cancers

   Measured: At Baseline visit and up to 5 years

7. Socio-demographic characteristics

   Socio-demographic characteristics will be evaluated based on the following data: professional, socio-family and socio-economic characteristics, education, family status, potential professional exposure(s)

   Measured: At Baseline visit and up to 5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

1. First posted21 Nov 2025
2. Study start2 Jul 2025
3. Primary completion31 Jan 2031 (estimated)
4. Study completion31 Jan 2031 (estimated)

Resources

• Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
• Other trials for Metastatic Lung CancerStudies of the same condition, open and under way.
• What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.